Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

immatics, Roche enter into cancer vaccine and immunotherapy deal

immatics biotechnologies GmbH and Roche today announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics.

13 Nov 2013

P400 predicts RCC outcome

Reduced expression of a senescence-associated protein is associated with worse outcome in patients with renal cell carcinoma, study findings show.

22 Oct 2013

Prognostic factors could aid RCC metastasectomy decisions

Researchers have identified four factors that are associated with survival time in patients who undergo metastasectomy for metastatic renal cell carcinoma.

22 Oct 2013

Stage and grade dominate RCC outcomes

Tumor grade and American Joint Committee on Cancer stage have emerged as the most important predictors of mortality in a competing risks analysis of patients undergoing nephrectomy for renal cell carcinoma.

22 Oct 2013

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

immatics biotechnologies closes €34 million Series D financing round

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a €34 million Series D financing round.

15 Oct 2013

Metastatic site impacts survival in targeted RCC treatment

Bone and liver metastases may have the heaviest impact on the survival of patients receiving targeted therapy for metastatic renal cell carcinoma, suggest data from the International Metastatic Renal Cell Carcinoma Database Consortium.

8 Oct 2013

Immune marker prognostic after non-clear cell RCC surgery

The preoperative neutrophil-to-lymphocyte ratio is associated with disease-free survival in patients undergoing resection of localized non-clear cell renal cell carcinoma, research shows.

24 Sep 2013

Amendment to renal cancer TNM staging proposed

Patients with pT3a renal cell carcinoma have markedly worse survival rates if they have both fat invasion and renal vein thrombosis, rather than just one of these factors, a study shows.

24 Sep 2013

Inflammatory marker may highlight aggressive RCC treatment need

Patients with metastatic renal cell carcinoma who have high preoperative levels of the inflammatory marker C-reactive protein may need intensive multimodal treatment to optimize their survival, say researchers.

24 Sep 2013

Metastatic site impacts survival in targeted RCC treatment

24 Sep 2013

Nuclea Biotechnologies Acquires Wilex' U.S. Subsidiary

...

9 Sep 2013

ESMO recognises oncologists with prestigious awards

The European Society for Medical Oncology, the leading pan-European organisation representing medical oncology professionals, announced today the recipients of the annual society's prestigious awards, recognising excellence in oncology.

5 Sep 2013

Tumor vessel density linked to mRCC treatment response

Changes in tumor vessel density correlate with response and resistance to anti-angiogenic therapy in patients with metastatic renal cell carcinoma, study findings suggest.

28 Aug 2013

Muscle density improves mRCC prognosis prediction

Patients with metastatic renal cell carcinoma treated with targeted therapies have a better prognosis if they also have a high quality of muscle, study findings indicate.

28 Aug 2013

Time to RCC recurrence prognostic threshold challenged

A large study confirms the prognostic value of time to recurrence after surgery for renal cell carcinoma, and also suggests the need to reduce the threshold for early recurrence.

28 Aug 2013

Findings support partial nephrectomy for T1b RCC

Partial nephrectomy and radical nephrectomy provide comparable cancer control for T1b renal cell carcinoma, yet use of the less radical approach has remained limited in the USA over recent years, study results show.

28 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

New data questions surgical options for treating kidney cancer

Surgery is often the first step in treating kidney cancer, and new data from the University of Rochester Medical Center, which contradicts earlier research, questions whether removal of only the tumor (partial nephrectomy) is better than removing the entire kidney (radical nephrectomy).

25 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013